

***In vivo* filtering of *in vitro* MyoD target data:**

An approach for identification of biologically relevant novel downstream targets of transcription factors.

Po Zhao¹, Jinwook Seo², Zuyi Wang³, Yue Wang³, Ben Shneiderman², and

Eric P Hoffman^{1*}

¹Research Center for Genetic Medicine
Children's National Medical Center
Washington DC 20010

²Department of Computer Science
and Human-Computer Interaction Laboratory
Institute for Advanced Computer Studies
and Institute for Systems Research
University of Maryland
College Park, MD 20742

³Department of Electrical Engineering and Computer Science
The Catholic University of America
Washington DC 20064

*** Correspondence:**

Eric P Hoffman
Research Center for Genetic Medicine
Children's National Medical Center
111 Michigan Ave, NW
Washington DC 20010
Phone: 202-884-6011
Fax: 202-884-6014
Email: ehoffman@cnmcresearch.org

Key Words: Muscle regeneration, Expression profiling, Microarray, MyoD, MRFs

Acknowledgements:

Supported by grants from NIH (3R01 NS29525-09; U01 HL66614-01; NO1-NS-1-2339) and the Muscular Dystrophy Association USA.

Abstract

We report a novel approach to identification of downstream targets of MyoD, where a published set of candidate targets from a well-controlled *in vitro* experiment [1] is filtered for relevance to muscle regeneration using a 27 time point *in vivo* murine regeneration series. Using both interactive hierarchical clustering (HCE) [2], and Bayes soft clustering (VISDA) [3,4]. We show that only a minority of *in vitro*-defined candidates can be confirmed *in vivo* (~50% of induced transcripts, and none of repressed transcripts). The concordance of the *in vitro*, *in vivo* datasets, and both HCE and VISDA analytical techniques showed strong support for 18 targets (13 novel) of MyoD that are biologically relevant during myoblast differentiation, including *Cdh15*, *L-myc*, *Hes6*, *Stam*, *Tnnt2*, *Fyn*, *Rapsn*, *Nestin*, *Osp94*, *Pep4*, *Mef2a*, *Sh3glb1* and *Rb1*.

1. Introduction

Muscle differentiation has been widely used as a model system for both embryonic development, and post-natal regeneration of tissues. Both processes require the expression of myogenic regulatory factors (MRFs), transcription factors that control the staged induction of genes important for interpretation of positional cues, proliferation, and differentiation of myogenic cells. To date, most MRFs are transcriptional factors of the basic helix-loop-helix family, with MyoD being the prototypical member, and the most extensively studied. All MRFs recognize a downstream target promoter motif, called the “E-box”, that share the consensus sequence of CANNTG. Most basic helix-loop-helix transcription factors function as heterodimers, and transcription regulation by MyoD has been extensively studied with regards to its binding partners (E-proteins, MEF2, Id proteins, Twist), binding sites (E-boxes), protein modulation (acetylation, phosphorylation), and upstream signaling molecules during embryonic myogenesis [5-16]. Although MyoD is important in embryonic myogenesis and postnatal muscle regeneration, there are very few known downstream gene targets of MyoD.

Experimental *in vitro* systems using inducible transcription factor or signaling molecule constructs in cultured cells are a mainstay of molecular biology. The emergence of expression profiling with microarrays has led to a powerful experimental design where expression profiling is done immediately after induction of the transcription factor to identify potential downstream targets across much of the genome [1,17,18]. The candidate targets derived from expression profiling can be compared to existing knowledge of previously characterized downstream targets (positive control), with follow

up studies using gel shifts, chromatin immunoprecipitation assays, and promoter construct assays to confirm the novel downstream targets.

It is clear that *in vitro* experimental systems have been critical to our knowledge of transcriptional cascades, and to our knowledge of biology in general. However, the relative simplicity and tightly controlled nature of *in vitro* experimental systems comes with the liability of unknown relevance to the *in vivo* state. Particularly worrying is the fact that the majority of *in vitro* systems utilize over-expression constructs, leading to non-physiological levels of specific proteins in the cultured cell under study. Many transcription factors function as heterodimers, as does MyoD, and non-physiological levels of the transcription factor is likely to alter affinity and binding to specific promoters. Thus, it is expected that supra-physiological levels of MyoD would activate transcription of target genes that are not similarly regulated by MyoD in the *in vivo* state (e.g. promiscuous, non-physiologically-relevant binding targets).

A recent study identified a large series of putative downstream targets of MyoD using embryonic fibroblast cultures transfected with an inducible MyoD expressing construct [1]. The study was very nicely designed, using cell cultures knocked-out for endogenous *MyoD* and *Myf5* expression, and also used cyclohexamide to block translation to limit the expression changes to those genes directly downstream of MyoD. Both spotted cDNA arrays (5103 elements), and Affymetrix murine mu6800 arrays (4144 probe sets) were used, and 83 genes found induced by MyoD, and 28 genes apparently repressed by MyoD (number was counted based on ref. [1] and its supplemental material). Confirmation of induced expression by northern blot was done for a few of the 111 genes identified (*M-cadherin*, *Rbl*, *Myogenin*, *Prdc*, and *Fstl*). As with any such

study, it becomes important to determine which of the potential downstream targets have relevance to either embryonic myogenesis, or post-natal muscle regeneration. Indeed, the authors found nearly as many genes down-regulated by MyoD as they did up-regulated genes. This is surprising given that MyoD is considered a transcriptional activator, and not a repressor, and suggests that there are likely confounding variables in *in vitro* experimental systems that are not currently understood, or able to be controlled.

We have previously reported an *in vivo* model for identification of downstream targets of MyoD by induction of staged muscle regeneration using cardiotoxin (CTX) injection [17]. We conducted a 6 time point expression profiling series, and found *in vivo* induction of MyoD expression at 12 hrs and 3 days after CTX injection. The 12 hr peak of MyoD expression was coordinately expressed with key repressor binding partners (Id), while the 3 day peak of MyoD expression correlated with expression of known downstream gene targets of MyoD binding and transcriptional activation (*acetylcholine receptor, desmin, Myogenin*). We studied coordinately expressed genes at the 3 day time point as candidates for downstream gene targets of MyoD, found potential E box binding sites in a subset of the temporal gene cluster, and showed that both *calpain 6* and *Slug* had E boxes in their promoters that gel shifted consistent with MyoD binding. We then went on to prove that *Slug* was a novel downstream target of MyoD by chromatin immunoprecipitation assays, and *in vitro* assays of *Slug* promoter constructs [17]. There were two major drawbacks to using our 6 time point series to systematically uncover large numbers of downstream targets of MyoD. First, the temporal resolution of our 6 time point series was relatively crude, and was unable to temporally distinguish induction of *MyoD* vs. induction of its downstream gene targets. Second, the *in vivo* experimental

system is fundamentally “noisy”. Specifically, MyoD is known to carry out its function in myogenic cell lineages, however there are multitudes of other, additional cell types in regenerating muscle (vasculature and vascular remodeling, inflammatory cells, connective tissue remodeling, etc). Thus, any temporal cluster of transcripts could derive from many different types of cells, other than the desired myoblasts.

Here, we overcame these two drawbacks using a novel experimental design. First, we increased the temporal resolution of our regeneration series to include 27 time points following CTX injection. This enabled temporal clustering with much higher resolution. To our knowledge, this is the most dense time series in any expression profiling study to date. Second, we took advantage of a recently published *in vitro* study, where an inducible *MyoD* construct was used to identify potential MyoD binding gene targets [1]. This nicely designed study included the use of *MyoD/Myf5* knockout cell lines, inhibition of translation using cyclohexamide, and used both cDNA and Affymetrix arrays to identify up- and down-regulated genes. We filtered the *in vitro* candidate gene list against our 27 time point series *in vivo* temporal series to identify those genes that were likely bone fide, biologically relevant downstream targets of MyoD.

2. Materials and Methods

2.1 Induction of staged muscle degeneration/regeneration

Staged skeletal muscle degeneration/regeneration was induced by injection of cardiotoxin (CTX) as previously described [17]. Two mice were injected in gastrocnemius muscles of both sides, and then sacrificed at each of the following time points: 0, 12h, 1d, 2d, 3d, 3.5d, 4d, 4.5d, 5d, 5.5d, 6d, 6.5d, 7d, 7.5d, 8d, 8.5d, 9d, 9.5d, 10d, 11d, 12d, 13d, 14d, 16d, 20d, 30d, and 40d.

At each time point, two of the four muscles showing the most extensive and consistent histological changes were used for expression profiling on individual GeneChips.

2.2 Expression profiling

Expression profiling using Affymetrix U74Av2 (12,488 probe sets) was done as previously described [17]. Quality control measures included >4-fold cRNA amplification (from total RNA/cDNA), scaling factors <2 to reach a whole-chip normalization of 800, and visual observation of hybridization patterns for chip defects (see <http://microarray.cnmcresearch.org> for further descriptions).

Gene lists at each time point are available on our web site (<http://microarray.cnmcresearch.org>, Programs in Genomic Applications). More detailed descriptions of methods for generating gene lists are also on the website (<http://microarray.cnmcresearch.org>, Programs in Genomic Application). All image files (.dat) and absolute analysis files (.chip) corresponding to each expression profile are also available on our database.

2.3 Data analysis

Probe set analysis results derived from Microarray Suite version 5.0 were used for temporal clustering as follows. The signal intensity values (absolute analyses) of the probe sets for all 54 profiles were loaded into GeneSpring. Further hierarchical clustering analysis was limited to probe sets with at least ten present calls (18.5%) in all 54 profiles and $p\text{-value} < 0.05$ for Kruskal-Wallis test, corrected with Benjamini and Hochberg False Discovery Rate. This was to eliminate the signal values of probe sets with 80% of “absent calls”, inclusion of which leads to considerable artefactual noise in temporal clustering, with random fluctuations at or below background hybridization levels showing “statistically significant” clustering with user- or candidate gene-defined patterns. A hierarchical clustering algorithm using Pearson correlation was used to temporally group those probe sets based on their expression pattern across the 27 time points.

Clustering analysis of the expression of MyoD downstream targets used Hierarchical Clustering Explorer and VISual Data Analyzer (VISDA) [2,4].

3. Results

3.1 Expression profiling of muscle degeneration/regeneration

Gastrocnemii of 54 mice were injected with CTX using a custom 10-needle manifold covering 1 cm² [17], with four separate gastrocnemii harvested at each of 27 time points from two CTX-inject mice (54 mice, 108 gastrocnemii). Two histologically-matched muscles from each time point were expression profiled (Affymetrix U74Av2). We have previously shown that the use of inbred mice eliminates most inter-individual variability in expression profiles [17]. Thus, the replicates used for expression profiling were sometimes from the same mouse, and sometimes from different mice, but we have shown that this does not introduce a confounding variable in the temporal profiles [17].

We filtered data for probe sets performing well and with significantly sufficient hybridization patterns using filters. We required >18.5% “present calls” for each gene (see ref. [17]) (e.g. ≥ 10 present calls in 54 U74A profiles) and a statistically significant difference between any two time points (p value < 0.05 using Kruskal-Wallis test, adjusted with Benjamini and Hochberg False Discovery Rate). 37.5% of genes on the U74A microarray survived the present call filter (4,687 of 12,488). Note that this filtering method reduces the sensitivity of the analysis for genes expressed at very low levels, but also increases the specificity of the analysis such that poorly performing probe sets with poor signal-to-noise ratios (SNRs) are not included in further analysis. Signal intensity probe set values for all 54 profiles for the 4,687 genes surviving the present call filter were then subjected to temporal clustering using GeneSpring software package.

3.2 Temporal clustering of a 27 time point muscle regeneration series.

We first used unsupervised hierarchical clustering to determine if the time series variable was the major variable in the 4,687 genes 54 profiles, as opposed to technical variables and sources of noise (inter-animal, inter-muscle, etc) (Appendix 1). This analysis showed good grouping of adjacent time points, indicating that the time variable was the major variable in the study. There was some mixing of profiles in the later time points of regeneration, however this was to be expected due to the fact that most regeneration is known to be complete by 2 wks post-CTX injection, and we therefore expected relatively little difference between the later profiles.

We then used supervised hierarchical clustering based on the time series to define temporal clusters (coordinately regulated groups) of transcripts (Appendix 2). This data agreed with our previous 6 time point report [17], but showed a larger number of temporal clusters due to the greater temporal resolution. General groups of genes involved in inflammation, myogenesis, and myofiber maturation (contractile proteins) are shown (Appendix 2). There were also novel clusters induced very late in regeneration that were correlated with either slow twitch myofiber maturation, and likely tendon remodeling.

All further analysis of this data set was focused on the early time points coinciding with the two peaks of endogenous MyoD induction at 12 hrs and 3 days (Figure 1A).

3.3 In vivo expression of in vitro MyoD downstream targets

Bergstrom et al [1] studied direct downstream targets of MyoD *in vitro* by inducing exogenous *MyoD* expression while blocking new protein synthesis in *MyoD*^{-/-}/*Myf5*^{-/-} mouse embryo fibroblasts. By using cDNA arrays and Affymetrix Genechips,

Bergstrom et al. identified 83 genes up-regulated by MyoD and 28 genes down-regulated by MyoD; each of these 111 was deemed a candidate for direct downstream targets of MyoD binding to each promoter.

We sought to define the subset of the 111 potential *in vitro* targets of MyoD that were biologically relevant for muscle regeneration. This was done by filtering the 111 putative targets against the 27 time point *in vivo* muscle regeneration expression profile series. Three different approaches were used: 1. hierarchical clustering using correlation coefficients; 2. hierarchical clustering using the interactive HCE program to visualize temporal groupings of the 111 genes [2]; and Bayes soft clustering using the VISDA program [4]. The latter is a statistically-principled approach of the entire 27 time point data series, with subsequent fitting of the 111 genes into statistically-defined gene clusters.

Of the 83 up-regulated and 28 down-regulated genes, 73/83 and 25/28 were represented by probe sets on the U74Av2 chip, respectively. We then used hierarchical clustering algorithm (Pearson correlation) to cluster increased and decreased genes respectively (Appendix 3, 4). We tested the up-regulated *in vitro* data set against the 27 time point series, and ran both the spotted cDNA and Affymetrix data of Bergstrom et al. separately (Appendix 3). The data is seen to resolve into temporal clusters, two of which map well with the induction of MyoD during muscle regeneration (Figure 1). Specifically, both the spotted cDNA candidates, and the Affymetrix candidates show a temporal cluster of approximately 25% of genes at the 12 hr time point (corresponding to the 12 hr peak of MyoD expression *in vivo*), and another 25% map to a second temporal cluster at 3 days (corresponding to the 3 day peak of MyoD expression *in vivo*). The

remaining 50% of genes show expression patterns that do not correlate with expression of MyoD during muscle regeneration *in vivo*. This analysis suggests that about 50% of the genes identified as potential downstream targets of MyoD *in vitro* are biologically relevant for muscle regeneration *in vivo*. In figure 1, we show expansion of the time point graph to the 0-8 day time frame for MyoD (Figure 1B), and for examples of mRNAs showing biological relevance in regeneration (Slug, Figure 1C; Hes6 Figure 1D), and one mRNA not showing relevance (Bin1, Figure 1E).

We conducted a similar analysis of genes that were found to be down-regulated in the Bergstrom et al. data set. Temporal clustering showed that very few of the down-regulated *in vitro*-defined MyoD targets corresponded to the temporal expression pattern of MyoD *in vivo* (Appendix 4). There was no visually apparent down-regulated gene clusters at either the 12 hr or 3 day time point (Appendix 4). This suggests that few, if any, of the genes down-regulated by MyoD *in vitro* are biologically relevant to muscle regeneration *in vivo*. This is perhaps expected, as MyoD has been shown to act as a transcriptional activator, and not a repressor. Thus, down-regulated genes may be an artifact of the *in vitro* assay system.

3.4 Increasing the confidence of temporal clustering: Application of HCE to cluster discovery.

There are many complementary methods emerging for cluster discovery in microarray data. One method to increase the resolution and sensitivity of temporal cluster discovery is through visual interaction with the program. In this manner, we can “supervise” the clustering based on our expectation of clusters conforming to the two peaks of MyoD expression (12 hrs, 3 days; Figure 1). The Hierarchical Clustering

Explorer program (HCE) permits rapid user manipulation of data analysis, so that different computational algorithms and stringencies of analysis can be employed in an interactive manner, optimizing the sought-after clusters using human visualization [2]. We applied HCE to the up-regulated and down-regulated *in vitro* targets, and searched for the most visually satisfying 12 hr and 3 day clusters (Figure 2A, Table I, Appendix 5). Complete linkage and average linkage methods were used to cluster up- and down-regulated genes respectively to achieve a better visualization of clusters. HCE was unable to identify visually satisfying clustering of the down-regulated cluster, as was the case with the GeneSpring analyses (Figure 2B; Appendix 6). However, HCE-filtered data showed the same 12 hr and 3 day temporal clusters, with considerable membership in the clusters shared with the default GeneSpring analyses (Table I, Appendix 5).

Taking both the GeneSpring and HCE output together, three major gene expression patterns were identified in muscle regeneration: up-regulation between 12h and 3day post-injection (20/73 genes, corresponding the 12h peak of *MyoD*), up-regulation around 3 day post injection (17/73 genes, corresponding to the 3 day peak of *MyoD*), and no up-regulation (36/73 genes). Thus, a total 37 (50.7%) genes showed increased *in vivo* expression corresponding to upregulation of *MyoD* expression *in vitro*.

Of the 25 *MyoD* direct down-regulated targets in Bergstrom's study, only six of them showed decreased expression in the muscle regeneration temporal series. Five of the genes did not show differential expression. In contrast, eleven of the genes showed up-regulation at various time points (Appendix 6). Three of the genes were called "absent" in all profiles, and thus not informative.

3.5 Clustering analysis of *in vitro* MyoD downstream targets using VISDA

A major disadvantage of the hierarchical clustering methods described above is that there is little statistical support for the data output. Thus, identification of clusters by supervised temporal hierarchical clustering can be considered a relatively non-robust method of data analysis. We therefore applied an alternative, more robust statistical analysis of the data using a recently described program, VISDA [4]. VISDA interrogates large data sets by first reducing the dimensionality of the temporal series by discriminatory data project and subsequent cluster decomposition by soft data clustering. This method of fitting a statistical model to the data set allows the selection of the number of clusters and definition of clusters statistically (cluster discovery). The data is then partitioned into the supported number of clusters, and further partitioned if desired.

Application of VISDA to the 54 profiles (probe sets were filtered by requiring more than 2 present calls in any of the profiles) suggested support for a minimum of 18 temporal clusters (Figure 3), with membership in each cluster ranging from 167 to 664 genes. VISDA detected the 3 day temporal cluster, and at 18 clusters split this into two clusters (clusters 1 and 10; Figure 3). Mapping of the Bergstrom et al. upregulated genes to the 18 VISDA clusters showed many to map to clusters 1 and 10, and these same genes showed visual segregation to the 3 day time point peak of *MyoD* by hierarchical clustering (Table I, Appendix 7A). The concordance of the GeneSpring, HCE, and VISDA analysis for 18 potential downstream targets at the 3 day peak of MyoD expression (VISDA clusters 1 and 10) provides strong support for these 18 genes representing biologically relevant downstream targets of MyoD involved in myoblast differentiation during muscle regeneration. These 18 genes were *Cadherin 15 (cdh15)*,

L-myc, Hairy and enhancer of split 6 (Hes6), Myogenin, cholinergic receptor $\alpha 1$ (Chrna1), cholinergic receptor gamma (Chrng), integrin $\alpha 7$ (Itga7), signal transducing adaptor molecule 1 (Stam), cardiac troponin T2 (Tnnt2), MyoD, Fyn, receptor-associated protein of the synapse (Rapsn), Nestin, osmotic stress protein 94 kDa (Osp94), peptidase 4 (Pep4), myocyte enhancer factor 2A (Mef2a), SH3-domain GRB2-like B1 (Sh3glb1), and retinoblastoma 1 (Rb1). Only myogenin, MyoD, Chrna1, Chrng, and Itga 8 have been previously characterized.

The down-regulated genes did not show good mapping to any specific VISDA cluster (Appendix 7B). Thus, VISDA was unable to provide any independent support for a down-regulated MyoD cluster corresponding to the peaks of MyoD expression. This data is consistent with the GeneSpring, and HCE data presented above, and also current knowledge of MyoD as a transcriptional activator, rather than a repressor.

4. Discussion

In vitro systems (e.g. cell culture) avoid many of the problems intrinsic to *in vivo* experimental systems. For example, cell culture systems used to dissect myogenic pathways typically employ pure cell populations, with synchronized response to the transcription factor under study (e.g. ref. [1]). While the *in vitro* experimental systems can be elegantly controlled, there are many issues which question relevance to the *in vivo* embryonic development or muscle regeneration. For example, during embryogenesis, cells in the dermatomyotome decide to become committed to the muscle lineage via positional cues provided by *Wnt* and *Shh* expression in neighboring cells. These positional cues are clearly lacking from the *in vitro* system. Likely, in muscle regeneration, myoblasts only proliferate and differentiate in the context of a pre-existing myofiber basal lamina. Indeed, the presence of a defective myofiber basal lamina precludes muscle regeneration, as evidenced by the failure of regeneration in both mice and humans lacking the basal lamina merosin protein (laminin alpha2) [19,20]. Thus, downstream targets of MyoD defined *in vitro*, may, or may not, have any relevance to muscle development or regeneration *in vivo*.

In this report, we combine the advantages of the *in vitro* experimental system, with an *in vivo* filter for biological relevance. Specifically, we used the excellent *in vitro* data set of potential MyoD downstream targets recently published [1], and filtered this against a 27 time point muscle regeneration series described here. The identification of the subset of *in vitro* downstream targets of MyoD that were biologically relevant for muscle regeneration was done by a series of data visualization and statistical methods, including hierarchical clustering (both supervised and unsupervised), HCE, and VISDA

Bayes soft clustering. Through these analyses, we provide support for approximately half of the candidates for transcriptional activation by MyoD reported by Bergstrom et al. (Figure 2, Table I, Appendix 3-5). We provide the strongest support for 18 downstream candidates, that we show by all methods to map to the second peak of MyoD expression at 3 days after CTX injection. These 18 genes are: *cdh15*, *L-myc*, *Hes*, *Myogenin*, *Chrna1*, *Chrng*, *Itga7*, *Stam*, *cardiac troponin T2*, *MyoD*, *Fyn*, *Rapsn*, *Nestin*, *Osp94*, *Pep4*, *Mef2a*, *Sh3glb1*, and *Rb1*. Of these 18, *Cdh15*, *L-myc*, *Hes6*, *Stam*, *Tnnt2*, *Fyn*, *Rapsn*, *Nestin*, *Osp94*, *Pep4*, *Mef2a*, *Sh3glb1* and *Rb1* are “novel” downstream targets of MyoD that have not been previously characterized outside of the expression profiling papers discussed here [1,17, this paper]. It is outside the scope of this current manuscript to describe the potential functional roles of each of these novel downstream MyoD targets in muscle regeneration. This will require further functional and molecular studies.

Importantly, we were unable to provide support for any of the potential down-regulated MyoD targets described by Bergstrom et al [1]. MyoD is well characterized as a transcriptional activator, where binding to E box sequences in target promoters leads to transcriptional induction of the downstream target gene. Thus, it was unexpected that a series of down-regulated transcripts were identified after *in vitro* induction of *MyoD* expression [1]. As translation was blocked by cycloheximide, these down-regulated transcripts suggested that MyoD might also act as a transcriptional repressor, perhaps by binding of specific partner proteins in a heterodimer [1]. If the down-regulated transcripts were biologically relevant, then we would have seen these transcripts temporally cluster into groups that were down-regulated at one of the two peaks of MyoD

expression *in vivo* (12 hrs, or 3 days). None of our methods (hierarchical clustering, HCE, VISDA) identified any such cluster.

This data suggests that the negatively regulated candidate genes defined by *in vitro* studies are likely experimental artifacts, and that MyoD does indeed function solely as a transcriptional activator. Alternatively, the downstream targets could be so selective that they do not cluster effectively. Also, downregulated genes at the 12 hr time point correspond to most myofibrillar proteins, as myofibers are being actively destroyed by macrophages at this time point. Thus, these few potential down-regulated targets may be poorly resolved by our *in vivo* data.

In conclusion, we have presented a novel experimental approach that combines the advantages of both the *in vivo* and *in vitro* experimental systems of studying muscle transcriptional cascades and regeneration. We propose that a similar combined data filtering approach can be applied to any tissue or cell type where similar stimuli can be provided both *in vitro* and *in vivo*.

References

- [1] Bergstrom D.A., Penn B.H., Strand A., Perry R.L., Rudnicki M.A., Tapscott S.J., Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression, *Mol Cell* 9 (2002) 587-600.
- [2] Seo J., Shneiderman B., Interactively exploring hierarchical clustering results, *IEEE Computer* 35 (2002) 80-86.
- [3] Wang Y., Luo L., Freedman M.T., Kung S.Y., Probabilistic principal component subspaces: a hierarchical finite mixture model for data visualization, *IEEE Trans Neural Networks* 11 (2000) 635-646.
- [4] Wang Z., Zhang J., Lu J., Lee R., Kung S.Y., Khan J., Clarke R., Wang Y., Discriminatory mining of gene expression microarray data, *J Signal Processing Systems* (2003) in press.
- [5] Benezra R., Davis R.L., Lockshon D., Turner D.L., Weintraub H., The protein Id: a negative regulator of helix-loop-helix DNA binding proteins, *Cell* 61 (1990) 49-59.
- [6] Sun X.H., Copeland N.G., Jenkins N.A., Baltimore D., Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins, *Mol Cell Biol* 11 (1991) 5603-5611.
- [7] Jen Y., Weintraub H., Benezra R., Overexpression of Id protein inhibits the muscle differentiation program: *in vivo* association of Id with E2A proteins, *Genes Dev* 6 (1992) 1466-1479.
- [8] Spicer D.B., Rhee J., Cheung W.L., Lassar A.B., Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist, *Science* 272 (1996) 1476-1480.
- [9] Huang J., Blackwell T.K., Kedes L., Weintraub H., Differences between MyoD DNA binding and activation site requirements revealed by functional random sequence selection, *Mol Cell Biol* 16 (1996) 3893-3900.
- [10] Hebrok M., Fuchtbauer A., Fuchtbauer E-M., Repression of muscle-specific gene activation by the murine Twist protein, *Exp Cell Res* 232 (1997) 295-303.
- [11] Black B.L., Olson E.N., Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins, *Annu Rev Cell Dev Biol* 14 (1998) 167-196.
- [12] Song A., Wang Q., Goebel M.G., Harrington M.A., Phosphorylation of nuclear MyoD is required for its rapid degradation, *Mol Cell Biol* 18 (1998) 4994-4999.
- [13] Tajbakhsh S., Borelle U., Vivarelli E., Kelly R., Papkoff J., Duprez D., Buckingham M., Cossu G., Differential activation of Myf5 and MyoD by different Wnts in explants of

mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5, *Development* 125 (1998) 4155-4162.

[14] Sartorelli V., Puri P.L., Hamamori Y., Ogryzko V., Chung G., Nakatani Y., Wang J.Y., Kedes L., Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program, *Mol Cell* 4 (1999) 725-734.

[15] Poleskaya A., Duquet A., Naguibneva I., Weise C., Vervisch A., Bengal E., Hucho F., Robin P., Harel-Bellan A., CREB-binding protein/p300 activates MyoD by acetylation, *J Biol Chem* 275 (2000) 34359-34364.

[16] Mal A., Sturniolo M., Schiltz R.L., Ghosh M.K., Harter M.L., A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program, *EMBO J* 20 (2001) 1739-1753.

[17] Zhao P., Iezzi S., Carver E., Dressman D., Gridley T., Sartorelli V., Hoffman E.P., Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration, *J Biol Chem* 277 (2002) 30091-30101.

[18] Mayanil C.S.K., George D., Freilich L., Miljan E.J., Mania-Farnell B., McLone D.G., Bremer E.G., Microarray analysis detects novel Pax3 downstream target genes, *J Biol Chem* 276 (2001) 49299-49309.

[19] Pegoraro E., Mancias P., Swerdlow S.H., Raikow R.B., Garcia C., Marks H., Crawford T., Carver V., DiCianno B., Hoffman E.P., Congenital muscular dystrophy (CMD) with primary laminin α 2 deficiency presenting as inflammatory myopathy, *Annals Neurol* 40 (1996) 782-791

[20] Hoffman E.P., Pegoraro E., Laminin alpha2 (merosin) gene mutations, in: Karpati G., (Ed), *Structural and Molecular Basis of Skeletal Muscle Diseases*. ISN Neuropathology Press, 2002, pp. 37-40.

Figure 1. Temporal profile of MyoD, and known and potential downstream target genes.

Panel A. Shown is the temporal profile of *MyoD* over the entire 27 time point series. *MyoD* shows biphasic induction only at very early time points following induction of regeneration by CTX. Error bars are derived from independent replicates at each time point.

Panel B. Shown is an expansion of the 0-8 day time point data, showing more clearly the expression pattern of *MyoD* with error bars.

Panel C. Shown is a well-characterized downstream target of MyoD, *Slug*, as we have previously described (Zhao et al. 2002). The temporal pattern of *Slug* expression is consistent with being downstream of MyoD after the second phase (3 day) of MyoD expression.

Panel D. Shown is an example of one of the potential novel downstream targets of MyoD (*Hes6*) determined by an *in vitro* experimental system (Bergstrom et al. 2002). This potential candidate shows a pattern consistent with activation by MyoD at the second phase of induction (3 day time point).

Panel E. Shown is an example of a potential novel downstream target of MyoD (*Bin1*) identified by *in vitro* profiling (Bergstrom et al. 2002) that does not fit with our *in vivo* temporal data. This gene was induced by MyoD *in vitro*, yet shows a pattern that is not consistent with activation by MyoD *in vivo*. This could be due to an embryonic-specific induction, or due to non-relevance to the *in vivo* state.

Figure 2. MyoD downstream targets *in vitro* have different expression patterns in muscle regeneration as shown by HCE. Shown is the hierarchical clustering of downstream targets of MyoD *in vitro*, based on their expression in muscle regeneration *in vivo*. For up-regulated genes *in vitro* (panel A, hierarchical clustering using the complete linkage), three major expression patterns were identified: up-regulation with a peak between 12h and day 3, up-regulation with a peak at day 3, and no up-regulation. The first two patterns correspond to 12h peak and day 3 peak of *MyoD* expression respectively. Ambiguous branches do not show a clear 12h or 3d upregulation pattern. For down-regulated genes *in vitro* (panel B, hierarchical clustering using the average linkage), expression of eleven genes was found increased, six genes were found down-regulated, five genes were not differentially regulated.

Figure 3. Clustering analysis using VISDA. Shown is the 18 temporal clusters derived from VISDA analysis. Number of genes in each cluster was listed in the table.

Table I. Expression of *in vitro* upregulated MyoD targets in muscle regeneration and in HCE and VISDA cluster

GenBank ¹	UniGene	Symbol	Gene Name	FC ²	TP ³	HCE ⁴ cluster	VISDA ⁵ cluster
Genes showing 3 day peak⁶							
AJ245402	-	cdh15	Cadherin 15 gene	+3.7	3d	3d	1
X13945	-	Lmyc-1	L-myc gene	+5.4	3d	3d	1
AW048812	Mm.29549	Hes6	Hairy and enhancer of split 6	+8.3	3.5d	3d	1
X15784	Mm.16528	Myog	Myogenin	+14.4	3.5d	3d	1
M17640	Mm.4583	Chrna1	cholinergic receptor, nicotinic, alpha polypeptide 1	+9.6	3.5d	3d	1
AV248455	Mm.2810	Chrng	cholinergic receptor, nicotinic, gamma polypeptide	+45	3.5d	3d	1
L23423	Mm.179747	Itga7	integrin alpha 7	+2.1	3.5d	3d	1
U43900	Mm.3965	Stam	signal transducing adaptor molecule 1	+2.8	3.5d	3d	1
L47600	Mm.632	Tnnt2	troponin T2, cardiac	+30	3.5d	3d	1
M18779	Mm.1526	Myod1	myogenic differentiation 1	+3.6	3d	Bi-ph	1
M27266	Mm.4848	Fyn	Fyn proto-oncogene	+3	3.5d	Bi-ph	2
X15788	Mm.1272	Rapsn	receptor-associated protein of the synapse, 43 kDa	+1.3	3.5d	Other	1
AW061260	Mm.23742	Nes	Nestin	+5	3.5d	Other	1
U23921	Mm.4150	Osp94	osmotic stress protein 94 kDa	+2.7	3.5d	Other	1
U51014	Mm.69751	Pep4	peptidase 4	+1.7	3d	3d	10
U94423	Mm.87279	Mef2a	myocyte enhancer factor 2A	+2.1	3.5d	3d	10
AI842874	Mm.182692	Sh3glb1	SH3-domain GRB2-like B1 (endophilin)	+1.6	3.5d	3d	10
M26391	Mm.304	Rb1	retinoblastoma 1	+1.8	3.5d	3d	10
Genes showing 12h-2d peak							
M18779	Mm.1526	Myod1	myogenic differentiation 1	+2.1	12h	Bi-ph	1
X54098	Mm.7362	Lmnb2	lamin B2	+2A	12h	12h/amb	1
U54803	-	Lice	cysteine protease	+2.4	1d	12h/amb	1
M27266	Mm.4848	Fyn	Fyn proto-oncogene	+2	12h	Bi-ph	2
M86183	Mm.7417	Ccnd3	cyclin D3	+2	1d	Other	2
D14883	Mm.4261	KAI1	Kangai 1	+2.5	12h	12h/amb	4
AF096875	Mm.21389	Dio2	deiodinase, iodothyronine, type II	+4.7	12h	12h/amb	5
M15832	Mm.738	Col4a1	procollagen, type IV, alpha 1	+2.3	12h	Other	9
AB012611	Mm.45048	Stam2	signal transducing adaptor molecule 2	+2.4	12h	12h/amb	10
M31690	Mm.3217	Ass1	arginosuccinate synthetase 1	+2	2d	12h/amb	14
X98475	-	VASP	vasodilator-stimulated phosphoprotein	+2.8	12h	Other	15
X14432	Mm.24096	Thbd	thrombomodulin	+12	12h	12h/amb	15
AF077861	-	Idb2	inhibitor of DNA binding 2	+6.4	12h	12h/amb	15
X61940	Mm.2404	Dusp1	Dual specificity phosphatase 1	+2.2	12h	12h/amb	16
Z19521	Mm.3213	Ldlr	low density lipoprotein receptor	+2.4	12h	12h/amb	16
AJ250723	Mm.38450	Sept9	Septin 9	+2.6	12h	12h/amb	18
X61172	Mm.2433	Man2a1	Mannosidase 2, alpha 1	+3	12h	12h/amb	18
U03434	Mm.14926	Atp7a	ATPase, Cu ⁺⁺ transporting, alpha polypeptide	+2.7	2d	12h/amb	18
D26532	Mm.4081	Runx1	Runt related transcription factor 1	+13.3	12h	12h/amb	18
AA791012	Mm.29766	Gmfg	Glia maturation factor, gamma	+6.4	12h	12h/amb	18
AW215736	Mm.181860	2310057H16Rik	Ricken cDNA 2310057H16 gene	+7.3	12h	12h/amb	18

1. GeneBank accession number used by Affymetrix probe sets.

2. FC- fold change
3. TP- time point
4. HCE cluster is determined by visualization of HCE output (Figure 6A). 3d- 3 day cluster; 12h- 12h cluster; amb - ambiguous branches; Bi-ph- Bi-phasic
5. VISDA clusters are as indicated in Figure 7.
6. Genes are grouped by visual examination of the expression pattern in GeneSpring.

Figure 1








Figure 2A




Figure 2B





Figure 3

Cluster#	# of Genes
1	402
2	378
3	291
4	471
5	448
6	279
7	654
8	419
9	378
10	467
11	360
12	554
13	520
14	463
15	400
16	167
17	291
18	628



Appendix 1. Unsupervised hierarchical clustering shows that the time series is the dominant variable relative to technical variables in the 27 time point expression series. Shown is unsupervised hierarchical clustering of 54 profiles (GeneSpring).

Expression profiles are clustered based on similarity. Four clusters can be distinguished, each of which correlates with different general stages of muscle regeneration. Cluster 1 corresponds to the stage of normal muscle and nearly completely regenerated muscle. Cluster 2 corresponds to the early stage with inflammation as the major event. Cluster 3 corresponds to the early muscle regenerating stage. Cluster 4 corresponds to the late muscle regenerating stage. While most profiles are clustered with appropriate periods of time, some discordance is seen between 5.5d and 14d. This may be due to non-synchronized satellite cell activation and differentiation, or more closely related profiles over this time period.

Appendix 2. Supervised (time series) hierarchical clustering of genes over a 27 time-point temporal series of muscle degeneration/regeneration expression profiles.

Shown is the dendrogram derived from the temporal hierarchical clustering algorithm (GeneSpring). Each row represents a time point of the time series averaged over two replicates at each time point (54 U74A profiles). Each vertical colored bar (lower part of figure) represents a single probe set (gene) in the profile (4,687 total). Vertical bars in red color indicate over-expression relative to the reference value, which is the median of the expression levels of the corresponding gene in all 54 profiles. Blue color represents under-expression relative to the median. The intensity of the color represents the confidence of the data, which generally correlates with the fold changes relative to the

reference value. This algorithm clusters genes with similar expression patterns based on correlation coefficients. The distance between two genes on the dendrogram reflects the temporal expression profile similarity.

Specific functional clusters are indicated (early inflammation cluster containing macrophage marker genes, myogenesis cluster, and myofibrillogenesis cluster).

Appendix 3. Filtering of genes up-regulated by MyoD in *in vitro*, against a 27 time point *in vivo* regeneration series.

Shown are potential downstream targets of MyoD defined by an *in vitro* cell-based assay system, defined by expression profiling with spotted cDNA arrays (Panel A), or Affymetrix arrays (Panel B), with expression of each gene studied as a function of muscle regeneration *in vivo*. Using Pearson's correlation coefficients for nearest neighbor analysis, the data from both the cDNA and Affymetrix gene sets resolves into at least three visually apparent temporal clusters. One cluster shows little expression at time 0, but with rapid increase in transcription at 12 hrs (12 hour cluster). A second cluster shows induction of transcription at 3 days. These two clusters correspond to the two peaks of MyoD expression *in vivo* during muscle regeneration (see Figure 3). This suggests that these two up-regulated gene clusters are likely biologically relevant to muscle regeneration, as their induction by MyoD *in vitro* correlates with temporally correct induction by MyoD *in vivo*. This also suggests that the majority of genes that are not contained in these two clusters are not biologically relevant to muscle regeneration.

Appendix 4. Genes showing down-regulation by MyoD *in vitro* do not cluster well with *in vivo* data.

Shown is the visualization of genes showing downregulation by *in vitro* induction of MyoD, detected using both spotted cDNA arrays (Panel A), and Affymetrix arrays (Panel B) (Bergstrom et al. 2002). Temporal hierarchical clustering of these 22 genes/probe sets using Pearson's correlation coefficient shows poor resolution of the data into temporal clusters (compare to Figure 4). Very few of the down-regulated genes show similar down-regulation at either the 12 hr or 3 day peak of MyoD expression. This analysis suggests that few of the down-regulated gene targets for MyoD are biologically relevant to muscle regeneration *in vivo*.

Appendix 5. Expression of *in vitro* upregulated MyoD targets in muscle regeneration and in HCE and VISDA cluster¹

Genes not showing upregulation at 12h to 3d							
D76432	Mm.3929	Zfx1ha	zinc finger homeobox 1a	-	-	Other	3
X04647	Mm.181021	Col4a2	procollagen, type IV, alpha 2	-	-	Other	3
AB026432	Mm.29623	Ddb1	damage specific DNA binding protein 1 (127 kDa)	-	-	Other	3
X58196	-	H19	H19	-	-	Other	3
U69176	Mm.2399	Lama4	laminin, alpha 4	-	-		3
M14537	Mm.86425	Chrnbl	cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)	-	-	Other	3
Y17138	Mm.686	Actc1	actin, alpha, cardiac	-	-	Other	4
X80903	Mm.4875	Dll1	delta-like 1 homolog (Drosophila)	-	-	12h/amb	4
M12347	Mm.89137	Acta1	actin, alpha 1, skeletal muscle	-	-	12h/amb	5
X59382	Mm.2766	Pva	parvalbumin	-	-	Other	5
L02526	Mm.1059	Map2k1	mitogen activated protein kinase kinase 1	-	-	12h/amb	6
U07617	Mm.6900	Grb2	growth factor receptor bound protein 2	-	-	12h/amb	7
AA023625	Mm.9213	Esr1	estrogen receptor 1 (alpha)	-	-	12h/amb	7
U62021	Mm.5142	Nptx1	neuronal pentraxin 1	-	-	Other	7
U68267	Mm.125614	Mybph	myosin binding protein H	-	-	Other	9
AA688834	Mm.17307	Rnpc2	ESTs, Weakly similar to SIG41 [M.musculus]	-	-	12h/amb	10
U64828	Mm.2028	Ncoa1	nuclear receptor coactivator 1	-	-		10
D14340	Mm.4342	Tjp1	tight junction protein 1	-	-	Other	10
AI835917	Mm.181309	2010003F24Rik	RIKEN cDNA 2010003F24 gene	-	-	Other	11
L12447	Mm.578	Igfbp5	insulin-like growth factor binding protein 5	-	-	Other	12
U13174	Mm.4168	Slc12a2	solute carrier family 12, member 2	-	-	Other	12
U43512	Mm.7524	Dag1	dystroglycan 1	-	-	Other	12
U60884	Mm.4383	Bin1	myc box dependent interacting protein 1	-	-	Other	13
AI852672	Mm.26550	Pfkm	phosphofructokinase, muscle	-	-	Other	13
AJ131021	Mm.32033	Rps6ka2	ribosomal protein S6 kinase, 90kD, polypeptide 2	-	-		13
J04992	Mm.39469	Tnni2	troponin I, skeletal, fast 2	-	-	Other	13
U15541	Mm.3841	Cox8b	cytochrome c oxidase, subunit VIIIb	-	-	Other	13
M74570	Mm.4514	Aldh1a1	alcohol dehydrogenase family 1, subfamily A1	-	-	Other	13
D38216	Mm.4519	Ryr1	ryanodine receptor 1, skeletal muscle	-	-	Other	13
L04966	Mm.22660	Rab18	RAB18, member RAS oncogene family	-	-	Other	13
X99963	Mm.687	Arhb	aplysia ras-related homolog B (RhoB)	-	-	12h/amb	14
AW122933	Mm.28107	Enpp2	ectonucleotide pyrophosphatase/phosphodiesterase 2	-	-	Other	17
D29016	Mm.3204	Fdft1	farnesyl diphosphate farnesyl transferase 1	-	-	Other	17
Z38015	Mm.6529	Dm15	dystrophia myotonica kinase, B15	-	-	Other	17
Genes absent							
AF026799	Mm.17911	Lgals6	lectin, galactose binding, soluble 6	-	-	-	-
M17031	Mm.22845	Src	Rous sarcoma oncogene	-	-	-	-
Genes not on U74Av2							
AI430906	Mm.179671	Tns	tensin	-	-	-	-

AI326148	Mm.725	Rpl7a	ribosomal protein L7a	-	-	-	-
AI323868	Mm.55	Rfp	ret finger protein	-	-	-	-
AI413515	Mm.14097	Tapbp	TAP binding protein	-	-	-	-
AI451071	Mm.25594	Prkar2b	protein kinase, cAMP dependent regulatory, type II beta	-	-	-	-
AI448706	Mm.105023	Spnb2	beta-spectrin 2, non-erythrocytic	-	-	-	-
W51433	-	-	-	-	-	-	-
W97775	Mm.39046	1110055E19Rik	RIKEN cDNA 1110055E19 gene	-	-	-	-
AA059763	-	-	Similar to tubulin beta 2	-	-	-	-
W12919	Mm.141443	Ldh1	lactate dehydrogenase 1, A chain	-	-	-	-

1. See table 1 for interpretation of symbol and grouping.

Appendix 6. Expression of *in vitro* down-regulated MyoD targets in muscle regeneration and in HCE and VISDA cluster¹

GenBank	UniGene	Symbol	Gene Name	FC	TP	VISDA cluster
Genes showing downregulation						
U03419	Mm.22621	Col1a1	procollagen, type I, alpha 1	-2.7	1d	2
X98055	Mm.2746	Gstt1	glutathione S-transferase, theta 1	-5	12h	6
L47480	-	BMP4	bone morphogenic protein 4	-2	3d	8
Y00516	Mm.16763	Aldo1	aldolase 1, A isoform	-3	2d	8
AI852765	Mm.24193	Gpc1	glypican 1	-5	2d	12
D29639	Mm.2491	Hadhsc	L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain	-9	2d	13
Genes not showing downregulation						
M92380	Mm.22763	Fstl	Follistatin-like	+3	3d	3
AA763466	Mm.22621	Col1a1	procollagen, type I, alpha 1	+2.5	5.5d	3
D13664	Mm.10681	Osf-2	osteoblast specific factor 2 (fasciclin I-like)	+33	5.5d	3
AF053943	Mm.4665	Aebp1	AE binding protein 1	+2.8	6.5d	3
AI848798	Mm.21549	Cryac	crystallin, alpha C	+2.2	12h	5
AA638816	Mm.368	Psmb4	proteasome (prosome, macropain) subunit, beta type 4	NC	-	7
AB011030	Mm.25760	Prdc	protein related to DAN and cerberus	NC	-	7
U62021	-	NPTX1	neuronal pentraxin 1	NC	-	7
U65636	Mm.368	Psmb4	proteasome (prosome, macropain) subunit, beta type 4	NC	-	11
X57024	Mm.10600	Glud	glutamate dehydrogenase	NC	-	14
L19932	Mm.14455	Tgfbi	transforming growth factor, beta induced, 68 kDa	+26	2d	15
X14678	Mm.192224	Zfp36	zinc finger protein 36	+4.7	12h	15
X83601	Mm.4663	Ptx3	pentaxin related gene	+7.6	12h	15
U49513	Mm.2271	Ccl9	chemokine (C-C motif) ligand 9	+45	1d	15
U27267	Mm.4660	Cxcl5	chemokine (C-X-C motif) ligand 5	+200	12h	15
L15429	Mm.856	Tm4sf1	transmembrane 4 superfamily member 1	+2	12h	16
Genes absent						
X51468	Mm.2453	Smst	somatostatin	-	-	-
AV145762	Mm.29564	Mmp2	matrix metalloproteinase 2	-	-	-
D30782	Mm.4791	Ereg	epiregulin	-	-	-
Genes not on U74Av2						
AI448727	Mm.33892	Copeb	core promoter element binding protein	-	-	-
AI429718	Mm.9944	Semcap3	semaphorin cytoplasmic domain-associated protein 3A	-	-	-
Z25524	-	-	integrin associated protein	-	-	-

1. See table 1 for interpretation of symbol and grouping.

Appendix 7. Mapping of potential *in vitro* down-stream targets of MyoD to VISDA clusters.


The 18 VISDA clusters are shown, with the mapping of each of the *in vitro* MyoD candidate target genes to the clusters. Panel A shows the Bergstrom et al. up-regulated genes, and Panel B shows the down-regulated genes.

The clusters corresponding to the biphasic MyoD induction pattern in muscle regeneration at 12 hrs and 3 days are shown by color (see also Figure 6). This shows that about 25% of the *in vitro* defined target candidates map to two clusters corresponding to induction at 3 days (see Table 1). This provides additional strong support for a 3 day cluster, and for these genes mapping to this cluster being likely *bona fide* downstream targets of MyoD at the 3 day time point. There was less support for genes showing temporal clustering to the 12 hr time point. This cluster did not resolve as well in the entire data set, and is likely merged with inflammatory gene clusters.

There was no support for a gene cluster corresponding to down-regulation by MyoD at either the 12 hr or 3 day time points. This is expected given the small number of candidates in this group, and the action of MyoD as a transcriptional activator.


Appendix 1

Probe set




Appendix 2


Probe set




Appendix 3A



Appendix3B




Appendix 4



Appendix 7A

Distribution of *in vitro* upregulated MyoD targets in VISDA clusters



Appendix 7B

Distribution of *in vitro* down-regulated MyoD targets in VISDA clusters

